Cannabidiol for Reduction of Brain Neuroinflammation

Study acronym: CBD
StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 8 more changesShow less
    • Final enrollment: 69 participants (planned 80)
    • Primary completion date changed from estimate of Sep 1, 2026 to Apr 17, 2026
    • Study completion date changed from estimate of Dec 15, 2026 to May 1, 2026
    • Eligibility criteria expanded, about 42 words
    • Secondary endpoints: details revised at 6 of 7 entries
    • Study description revised
    • Site details revised
    • Publications: details revised at 1 of 1 entry
  2. 3 versions Re-verified since Aug 31, 2024, no change to tracked fieldsv11-v13
  3. Eligibility criteria expanded, about 20 wordsv10
  4. Eligibility criteria shortened, about 12 wordsv9
  5. Re-verified, no change to tracked fieldsv8
Show 6 earlier versionsHide 6 earlier versions
  1. Eligibility criteria expanded, about 10 wordsv7
  2. Re-verified, no change to tracked fieldsv6
  3. Primary endpoint revised
    • Secondary endpoints revised (7)
    v5
  4. Eligibility criteria expanded, about 10 wordsv4
  5. Re-verified, no change to tracked fieldsv3
  6. Trial status: Not Yet Recruiting to Recruitingv2 Show 6 more changesShow less
    • Start date changed from estimate of Oct 1, 2021 to Jan 4, 2022
    • Eligibility criteria shortened, about 12 words
    • Secondary endpoints: 4 to 7
    • Primary endpoint revised
    • Site details revised
    • Study description expanded, about 2 words
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will investigate whether cannabidiol (CBD), the primary centrally and peripherally active non-intoxicating compound in the cannabis plant, exerts anti-neuroinflammatory effects in patients with chronic low back pain (cLBP) with or without mild-to-moderate depression.
Trial Details
NCT Number NCT05066308
Lead Sponsor Massachusetts General Hospital
Conditions
(from sponsor)		 Back Pain, Depressive Symptoms
Related terms Back Pain, Depression, Marijuana Abuse
Enrollment 69 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov